Firefly Aerospace plans to launch a new "lunar imaging service" called Ocula, which will collect detailed imagery using a set of moon-orbiting spacecraft.

Use of artificial intelligence–assistance software for HER2-low and HER2-ultralow IHC interpretation training to improve diagnostic accuracy of pathologists and expand patients' eligibility for ...

Trastuzumab deruxtecan (T-DXd) monotherapy in advanced HER2-positive or HER2-low/ultralow breast cancer: An updated pooled analysis of prospective clinical trials.

Samsung's venture arm is looking to invest in California-based medical device startup Exo, Bloomberg reported.

AI could help pathologists identify HER2-low and HER2-ultralow breast cancers with greater accuracy, according to findings scheduled for presentation at ASCO Annual Meeting.In a study of more than ...

Bayer today announced the launch of its Imaging Core Lab Services under the brand name Centafore. With over 25 years of experience supporting more than 200 c ...

Assistance from artificial intelligence can potenially increase the number of patients eligible for treatment for HER2-low breast cancers.

RemeGen's China readout bodes well for Pfizer’s own global phase 3 trial that pairs disitamab vedotin with Keytruda in in first-line bladder cancer.

Topline data were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki followed by THP in patients with high-risk, locally advanced HER2-positive early stage breast cancer.

Zongertinib elicited meaningful results in previously treated patients with HER2-mutated, advanced non–small cell lung cancer.

Abpro and Celltrion announce a partnership to develop ABP-102/CT-P72, a promising therapy for HER2-positive cancers.